Cleveland Clinic has selected PierianDx to utilize its integrated “one space” workflow and analysis solution, Clinical Genomicist Workspace (CGW), to advance precision medicine for patients. By joining the PierianDx customer network, Cleveland Clinic can now access the shared constitutional and somatic genomic data within CGW’s knowledge base, a robust database comprised of millions of biomedical findings driven by public and highly curated sources.PierianDx enables clinical labs to deliver
Read More
Impact of Precision Medicine| News, Policy, Analysis, Insights - HIT Consultant
NIH Awards UCSF Researchers $11.7M Grant to Launch Pediatric Precision Medicine Equity Program
The National Institutes of Health (NIH) has awarded a team of UC San Francisco researchers with a four-year $11.7 million grant to launch a new Prenatal and Pediatric Genomic Sequencing (P3EGS ) program at UCSF, according to UCSF news. Over the four-year span, the program is focused on pursuing equity in the implementation of genomic precision medicine for children and families in the San Francisco Bay Area.As part of the pediatric precision medicine program, the P3EGS team will recruit 1,100
Read More
Cara Raises $2M for First Precision Medicine App for Digestive Health
Cara, a Berlin-based digital health startup has raised $2 million in seed funding led by Atlantic Labs along with a group of undisclosed angel investors. Known as “poop-tech”, the company has launched the first precision medicine solution for digestive health. In 2016, HiDoc Technologies launched the Cara app with the aim to help people with chronic digestive disorders. Today, more than 20% of the world’s population suffer from the Irritable Bowel Syndrome (IBS), Inflammatory Bowel Disease
Read More
University of Chicago Medicine, Tempus Partner on Personalized Pancreatic Cancer Project
Pancreatic cancer is the third leading cause of cancer-related death in the United States. It has a five-year survival rate of just nine percent. Lack of effective treatments and early detection methods contribute to this grim prognosis. Personalized approaches to match a patient’s genomic information to therapies have led to improvements in treatment of other cancer types. None of the genetic mutations commonly seen in pancreatic cancer, however, have “druggable” targets.That’s why the
Read More
Philips Launches Informatics Platform to Advance Drug Research & Biomarker Discovery
Today, Philips has announced the launch of Xplore, a web-based image and data management platform that will help pharma and academic researchers speed up drug research and biomarker discovery through enhanced integration, visualization and analytics tools. Xplore v4.0 will be available commercially in July 2017. Customers have the option to purchase the basic package or with custom additions including a dedicated TMA module for enabling faster and streamlined research.As the industry continues
Read More
Kenzen Raises $5M to Expand Real-Time Sweat Analysis Wearable That Measures Biometrics
Kenzen, a developer of a next-generation wearables platform that continuously monitors, predicts and prevents avoidable health conditions using non-invasive sweat analysis has raised $5 million in funding. The round’s strategic investors include Digitalis, Flex (formerly Flextronics), the San Francisco 49ers, Hickory Ventures, Gaingels, and the Women’s Capital Connection. The company plans to utilize the funding to expand further development, support and market positioning of its ECHO Smart
Read More
Northwestern, Tempus Expand Partnership to Accelerate Personalizing Care for Cancer Patients
The Robert H. Lurie Comprehensive Cancer Center of Northwestern University is expanding its partnership with Tempus aimed at personalizing care for cancer patients. Tempus provides molecular sequencing and clinical analytic solutions for top academic centers, hospital systems, associations, and healthcare providers.As part of the expanded collaboration, Tempus will provide molecular sequencing and analysis for patient derived xenograft (PDX) models and patient derived organoid models, which will
Read More
Precision Medicine Startup AltheaDx Lands $27M to Expand Personalized Therapeutic Decisions Internationally
AltheaDx, Inc., a San Diego, CA-based commercial stage molecular diagnostics company specializing in the field of personalized medicine has raised $27 million in Series D funding. The company is a CAP-accredited, CLIA-certified laboratory and plans to utilize the funding to expands its sales force and marketing efforts to grow internationally.IDgenetix, the company’s product testing portfolio, enables personalized therapeutic decisions for patients suffering from some of the most prevalent
Read More
Aurora Cancer Care Launches Precision Medicine Program To Help Patients Gain More Access to Clinical Trials
Aurora Cancer Care, a not-for-profit health care provider in Wisconsin and northern Illinois is launching a precision medicine program powered by Syapse, a provider of precision oncology solutions. The new oncology precision medicine program will help physicians and researchers provide more care options for patients whose cancer is resistant to conventional treatment options like radiation and chemotherapy.The new multi-disciplinary Oncology Precision Medicine Clinic will be located inside
Read More
Aprima EHR Integrates With ActX to Bring Precision Medicine Into The Physician’s Office
Aprima, a physician pratice-focused EHR provider has announced an integration partnership with Genomic Decision Support platform ActX to bring precision medicine into the physician’s office. The addition of the ActX platform provides Aprima clients with access to genomics in everyday patient care and delivers clinically actionable insights that facilitate personalized medication and screening choices based on a patient’s unique genetic profile.Imagine, during your office visit, your physician
Read More
